GHENT, Belgium – (COMMERCIAL THREAD) –Therapeutic Confo today announced the creation of its Medical Advisory Board (MAB). MAB will provide external review and strategic advice for the company’s clinical development program, including the future direction of CFTX-1554, Confo’s leading preclinical candidate in the field of neuropathic pain.
MAB’s international members bring comprehensive clinical and translational expertise with extensive experience in various aspects of neuropathic pain, Confo’s initial area of interest. MAB will be chaired by Professor Andrew Rice, Professor of Pain Research at Imperial College London, UK.
Paolo Vicini, Director of Development at Confo Therapeutics, said: “The creation of a Medical Advisory Board is an important step for our evolving organization as we continue to develop into a clinical stage R&D company. We look forward to improving and expanding our development strategy by applying the various skills and perspectives exemplified by our MAB members, particularly as we move the CFTX-1554 into the clinic.
Professor Andrew Rice, Chairman of Confo’s Medical Advisory Board, added: “I am delighted to chair Confo Therapeutics’ newly formed Medical Advisory Board as the company continues to move forward in developing compelling treatment options in an indication. otherwise underserved. My colleagues and I hope that the company’s work on neuropathic pain will ultimately provide innovative therapies for patients.
“We are grateful to work with this hub of globally recognized clinical scientists and pain specialists,” said Cedric Ververken, CEO of Confo Therapeutics. “Backed by this MAB, we are confident in our ability to rapidly execute our common mission of creating a strong pipeline of high-value GPCR modulators derived from our pioneering drug discovery platform. ”
Confo Therapeutics MAB members are listed below. Member biographies are also available on the Confo website.
Ralf Baron, MD, Head of the Department of Neurological Pain Research and Therapy, Department of Neurology, University of Kiel, Germany.
Dr. Baron’s research focuses on exploring the mechanisms behind the formation of nerve pain, as well as the treatment of neuropathic pain syndromes. He participated in the development of a mechanism-related phenotyping strategy for patients with neuropathic pain.
Robert H. Dworkin, PhD, Professor of Anesthesiology and Perioperative Medicine, Neurology and Psychiatry, University of Rochester Medical Center, NY, USA.
Professor Dworkin is the Director of the Public-Private Partnership for Analgesics, Anesthetics and Addictions Clinical Trials Translations, Innovations, Opportunities and Networks (ACTTION) with the United States Food and Drug Administration. His main research interests include methodological aspects of clinical trials of analgesics and the treatment and prevention of chronic neuropathic and musculoskeletal pain.
Nanna Brix Finnerup, DrMedSc, MD, Professor and Chairman, Danish Pain Research Center, Department of Clinical Medicine, University of Aarhus, Denmark.
Prof. Finnerup’s research on the pathophysiology and therapy of neuropathic pain includes central and peripheral neuropathic pain, assessment of pain mechanisms, and stratified clinical trials.
Nathaniel Katz, MD, Scientific Director, Analgesic Solutions, Wayland, MA, USA.
Dr Katz has completed numerous clinical trials of pain treatments, both industry initiated and researcher initiated, involving pharmaceuticals, non-pharmaceutical pain relievers and devices. He is widely regarded as a world expert in postherpetic neuralgia pain management. He chaired the FDA Pain Division Advisory Board (2000-2004) and is currently the Scientific Director of WCG Analgesic Solutions.
Andrew SC Rice, MD, FRCP, FRCA, FFPMRCA, FFPMCAI (President of MAB), Pain Research Professor, Imperial College London, UK.
Professor Rice is active in translational research and clinical practice in the area of neuropathic pain. Much of his current work focuses on in-depth profiling and genotyping of cohorts of patients living with neuropathic pain.
Mark Versavel, MD, PhD, MBA, President of vZenium LLC, Boston, MA, USA.
Dr Versavel has over 25 years of clinical development experience in the field of neuropathic pain and in multiple indications in neurology and psychiatry in the areas of clinical pharmacology, early and late phase clinical trials and in support of marketed products.
About the CFTX-1554
CFTX-1554 is Confo Therapeutics’ first product candidate in preclinical development and is designed to treat peripheral neuropathic pain while avoiding centrally mediated side effects, such as addiction and sedation. The compound is a novel angiotensin II receptor type 2 inhibitor, or AT2R, a clinically validated target for the treatment of neuropathic pain. While clinical stage compounds targeting AT2R have not progressed due to side effects and / or toxicity concerns, CFTX-1554 interacts more efficiently with the AT2R binding site, which improves drug properties. Confo has initiated Phase I studies and aims to advance CFTX-1554 into clinical development once these studies are successfully completed.
About Confo Therapeutics
Confo Therapeutics’ unparalleled technology stabilizes the functional conformations of GPCRs (G protein coupled receptors) to uncover a wide range of previously inaccessible drug targets. This platform, combined with the pharmacological and biological information it provides, allows Confo to create a multi-indication pipeline of drug candidates with the vision of transforming therapeutic outcomes for patients with severe disease and lacking modifying therapies. of disease. Confo Therapeutics was formed out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Backed by international investors with a focus on life sciences and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies , Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.
For more information visit www.confotherapeutics.com